Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Incyte Corporation.

The Latest Advances in Treatment of GvHD: Where Are We and Where Are We Going?

Release Date: April 6, 2021
Expiration Date: April 6, 2022

Activity Overview

Graft-versus-host disease (GvHD) is the most common cause of life-threatening complications following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Acute GvHD is the second leading cause of death, after disease relapse, in patients undergoing allo-HSCT. Chronic GvHD is often preceded by acute GvHD and occurs in 30% to 70% of patients. Prophylaxis regimens show promise in improving clinical outcomes in patients with allo-HSCT–related complications, and therapies targeting Janus kinase 1/2 and Bruton’s tyrosine kinase have demonstrated effectiveness in both acute and chronic GvHD. Biomarkers have the potential to significantly improve a physician’s ability to determine risk for patients who have undergone allo-HSCT, who have not yet developed GvHD and aid in evaluating patient response to GvHD therapy. As new data in GvHD therapies are reported, hematologists need to receive education and support on how best to incorporate new strategies into their practice.

In this CME activity, 3 faculty experts in GvHD discuss recent advances in therapies for acute and chronic GvHD, as well as prophylactic treatment strategies, and present a case study that highlights the incorporation of biomarker data into the care of patients with GvHD. In their discussion, they share their experiences in caring for patients with GvHD, provide insight into clinical trial data, and offer strategies for integrating new therapeutic approaches into clinical practice.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Incyte Corporation.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward hematologists, medical oncologists, researchers, and investigators who treat, or are interested in the treatment of hematologic malignancies. Other allied health care professionals, including nurse practitioners, physician assistants and nurses involved in the treatment and management of patients with hematologic malignancies will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Summarize recent advances to understand the mechanisms that underlie GvHD development to better inform clinical decision-making
  • Integrate current approaches for the prophylaxis and treatment of GvHD into clinical practice
  • Explain unmet clinical needs in GvHD management and the role of emerging approaches and therapies to bridge these gaps in care

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


James L.M. Ferrara, MD, DSc
James L.M. Ferrara, MD, DSc
Ward-Coleman Chair in Cancer Medicine
Professor and Director,
Hematologic Malignancies Translational Research Center
The Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Consultant: Eurofins Viracor; Other: Royalties from Eurofins Viracor.

Professor Ernst Holler, MD, PhD
Professor Ernst Holler, MD, PhD
Senior Professor on Allogeneic Stem Cell Transplantation
Former Director of the Allogeneic Stem Cell Transplantation Program
Department of Internal Medicine III (Hematology and Oncology)
University of Regensburg
Regensburg, Germany

Disclosures: Grant Research Support: Medac Germany; Consultant: MaaT Pharma, France; Medac Germany; Novartis; Speakers Bureau: Jazz Pharmaceuticals; Neovii.

Carrie Lynn Kitko, MD
Carrie Lynn Kitko, MD
Associate Professor of Pediatrics
Ingram Professorship in Pediatric Oncology
Medical Director, Pediatric Stem Cell Transplantation Program
Vanderbilt University Medical Center
Nashville, TN

Disclosures: Carrie Lynn Kitko has no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By